Cancer News and Research

Latest Cancer News and Research

BioInvent, ThromboGenics initiate TB-402 Phase IIb trial for VTE prophylaxis

ThromboGenics NV and co-development partner BioInvent International announce today that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism after total hip surgery.

27 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

ISC-4 topical compound may prevent skin cancer lesion formation

While incidents of melanoma continue to increase despite the use of sunscreen and skin screenings, a topical compound called ISC-4 may prevent melanoma lesion formation, according to Penn State College of Medicine researchers.

27 Apr 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

AAN honors BIDMC neurologist with Epilepsy Award

Bernard Chang, MD, a member of the Department of Neurology at Beth Israel Deaconess Medical Center and Assistant Professor of Neurology at Harvard Medical School, received the Dreifuss-Penry Epilepsy Award at the 63rd Annual Meeting of the American Academy of Neurology, held recently in Honolulu, HI.

27 Apr 2011

Motor regulatory protein can block human ovarian tumor growth

A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.

27 Apr 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Omega 3 rich oils fall from grace: May raise prostate cancer risk

...

26 Apr 2011

Black people more likely to exhaust financial resources for cancer therapy than whites: Study

In a new study published online in the journal Cancer, it was said that when faced with life-threatening cancer, minority patients like blacks may be more likely to drain their bank accounts to extend life than whites.

26 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

New angle in cause of tuberculosis discovered - scientists hopeful for new therapy

In a new study published Monday, researchers from the US have isolated the enzyme that allows tuberculosis to destroy lung tissue. This discovery could speed the search for treatments.

26 Apr 2011

Most Americans unaware of recommended alcohol limits and risks of sea salt

Most Americans believe drinking wine is good for your heart but are unaware of recommended alcohol limits, and most mistakenly believe sea salt is a low-sodium alternative to regular table salt, according to a new survey about these common products.

26 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

Accuray announces expiration of HSR waiting period for TomoTherapy acquisition

Accuray Incorporated, a global leader in the field of radiosurgery, today announced the expiration of the mandatory, pre-merger waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, in connection with the previously announced acquisition of TomoTherapy Incorporated.

26 Apr 2011